GH/IGF-1 Abnormalities and Muscle Impairment: From Basic Research to Clinical Practice

Otros/as autores/as

Institut Català de la Salut

Unitat de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERDEM (ISCIII), Universitat Autònoma de Barcelona, Bellaterra, Spain

Vall d'Hebron Barcelona Hospital Campus

Fecha de publicación

2022-06-14T07:33:46Z

2022-06-14T07:33:46Z

2021-01-02



Resumen

Acromegaly; Growth hormone; Myopathy


Acromegalia; Hormona de crecimiento; Miopatía


Acromegàlia; Hormona del creixement; Miopatia


The impairment of skeletal muscle function is one of the most debilitating least understood co-morbidity that accompanies acromegaly (ACRO). Despite being one of the major determinants of these patients’ poor quality of life, there is limited evidence related to the underlying mechanisms and treatment options. Although growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels are associated, albeit not indisputable, with the presence and severity of ACRO myopathies the precise effects attributed to increased GH or IGF-1 levels are still unclear. Yet, cell lines and animal models can help us bridge these gaps. This review aims to describe the evidence regarding the role of GH and IGF-1 in muscle anabolism, from the basic to the clinical setting with special emphasis on ACRO. We also pinpoint future perspectives and research lines that should be considered for improving our knowledge in the field.

Tipo de documento

Artículo


Versión publicada

Lengua

Inglés

Publicado por

MDPI

Documentos relacionados

International Journal of Molecular Sciences;22(1)

https://doi.org/10.3390/ijms22010415

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

Este ítem aparece en la(s) siguiente(s) colección(ones)